2017 revenues: $10,561,000,000
2017 R&D spend: $617,000,000
Fiscal year ending: December 31, 2017
José (Joe) Almeida, chairman, president & CEO; Giuseppe Accogli, SVP & president, global businesses; Brik Eyre, SVP & president, Americas; Andrew Frye, SVP & president, APAC; Sean Martin, SVP & general counsel ; Jeanne Mason, SVP, HR; Scott Pleau, SVP, operations; James Saccaro, EVP & CFO; Scott Bohaboy, SVP, treasurer & global planning head; Caroline Karp, SVP & controller; Paul Martin, SVP & CIO; Ellen McIntosh, SVP & corporate secretary; Dennis Crowley senior vice president, business development & licensing; Stacey Eisen, senior vice president, global communications & president and executive director, Baxter International Foundation; Cristiano Franzi, senior vice president and president, EMEA; Jacqueline (Jackie) Kunzler, senior vice president, chief quality officer; Dr. Sumant Ramachandra, senior vice president, chief science and technology officer
Baxter continued its buying spree since closing the $625 million pickup of Claris Lifescience’s injectable drug business last year: in March, the company paid $153 million to acquire hemostat and surgical sealant assets from Mallinckrodt Pharmaceuticals. Baxter reeled in a number of regulatory wins this year, including the August 2018 CE Mark clearance and regulatory approval in Australia for its Evo IQ infusion system. Earlier this year, Baxter landed FDA approval for its Spectrum IQ infusion system with Dose IQ safety software, touting the system as the first to include bi-directional electronic medical records integration.
You may also like: